Pulmatrix, Inc. (PULM)
NASDAQ: PULM · IEX Real-Time Price · USD
2.040
-0.030 (-1.45%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Pulmatrix Revenue
In the year 2023, Pulmatrix had annual revenue of $7.30M with 20.21% growth. Revenue in the quarter ending December 31, 2023 was $2.20M with 28.92% year-over-year growth.
Revenue (ttm)
$7.30M
Revenue Growth
+20.21%
P/S Ratio
1.02
Revenue / Employee
$331,727
Employees
22
Market Cap
7.45M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
| Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
| Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
| Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
| Dec 31, 2019 | 7.91M | 7.76M | 5,069.93% |
| Dec 31, 2018 | 153.00K | -182.00K | -54.33% |
| Dec 31, 2017 | 335.00K | -500.00K | -59.88% |
| Dec 31, 2016 | 835.00K | -366.00K | -30.47% |
| Dec 31, 2015 | 1.20M | 849.00K | 241.19% |
| Dec 31, 2014 | 352.00K | - | - |
| Mar 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionPULM News
- 4 weeks ago - Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives - PRNewsWire
- 6 months ago - Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 7 months ago - Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine - PRNewsWire
- 8 months ago - Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole - PRNewsWire
- 9 months ago - Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 10 months ago - Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine - PRNewsWire
- 11 months ago - Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society - PRNewsWire